Clinical Trial

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate whether maintenance therapy with Zanubrutinib monotherapy could improve the 2-year progression free survival (PFS) of patients with mantle cell lymphoma who had remission after first-line immunochemotherapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-25.
Trial Details
NCT Number NCT06341556
Lead Sponsor Fudan University
Conditions Mantle Cell Lymphoma, Maintenance Therapy
Enrollment 52 participants
Start Date 2024-05-24
Primary Completion 2026-03 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2024-09-04